BLAINJECTIONINJECTABLEPriority Review
Approved
Jul 2024
Lifecycle
Growth
Competitive Pressure
30/100
Data completeness
3/8 — Basic
Priority Review
KISUNLA (donanemab-azbt) by Eli Lilly and Company is donanemab-azbt is a humanized immunoglobulin gamma 1 (igg1) monoclonal antibody directed against insoluble n-truncated pyroglutamate amyloid beta. First approved in 2024.
Drug data last refreshed 3h ago · AI intelligence enriched 3d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
KISUNLA (donanemab-azbt) is a humanized IgG1 monoclonal antibody targeting insoluble N-truncated pyroglutamate amyloid beta, approved July 2024 for early Alzheimer's disease. It reduces amyloid beta plaques in the brain, a defining pathophysiological hallmark of Alzheimer's disease. The drug is administered by intravenous injection.
Growth
Early-stage growth product with significant market potential in neurodegenerative disease; expect expanding commercial teams and field infrastructure build-out.
Mechanism of Action
Donanemab-azbt is a humanized immunoglobulin gamma 1 (IgG1) monoclonal antibody directed against insoluble N-truncated pyroglutamate amyloid beta. The accumulation of amyloid beta plaques in the brain is a defining pathophysiological feature of Alzheimer's disease. Donanemab-azbt reduces amyloid…
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
KISUNLA offers growth-stage career opportunity in a high-visibility Alzheimer's disease franchise at Eli Lilly with established oncology and neurology expertise. Early commercial lifecycle means team expansion, field training, and payer education roles are active, but limited by the 0 currently linked job postings.
Brand Manager
Worked on KISUNLA at Eli Lilly and Company? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.